Email updates

Keep up to date with the latest news and content from BMC Pharmacology and Toxicology and BioMed Central.

Open Access Highly Accessed Research article

Hit identification of IKKβ natural product inhibitor

Chung-Hang Leung1*, Daniel Shiu-Hin Chan2, Ying-Wei Li3, Wang-Fun Fong3 and Dik-Lung Ma2*

Author Affiliations

1 State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China

2 Department of Chemistry, Hong Kong Baptist University, Kowloon Tong, Hong Kong

3 Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong

For all author emails, please log on.

BMC Pharmacology and Toxicology 2013, 14:3  doi:10.1186/2050-6511-14-3

Published: 7 January 2013

Additional files

Additional file 1:

Figure S1. Chemical structures of the 11 other high-scoring compounds selected for preliminary biological evaluation. Figure S2. Preliminary experimental screening of the 12 compounds on inhibition of cellular IKKβ mediated NF-κB activity. Table S1. Chemical name and structures of benzoic acid derivatives reported to target the NF-κB signaling pathway. Table S2. Lowest-energy binding pose of the 11 other compounds with the ATP binding site in the KD domain of IKKβ. Table S3. Binding poses and ICM docking energies of compound 1 to other four kinases. The reference compounds are displayed in cyan.

Format: DOCX Size: 6.9MB Download file

Open Data